Abstract
Chemotherapeutic DNA alkylating agents are common weapons employed to fight both pediatric and adult cancers. In addition to cancerous cells, nontarget tissues are subjected to the cytotoxicity of these agents, and dose-limiting toxicity in the form of myelosuppression is a frequent result of treatment. One approach to prevent myelosuppression that results from the use of chemotherapeutic agents is to increase the levels of DNA repair proteins in bone marrow cells. Here we report our second successful attempt to create a fusion protein that possesses both direct reversal and base excision repair pathway DNA repair activities. The chimeric protein is composed of the human O6-Methylguanine-DNA Methyltransferase (MGMT) and the yeast Apn1 proteins and retains both MGMT and AP endonuclease activities as determined by biochemical analysis. We have also demonstrated that the chimeric protein is able to protect mammalian cells from the DNA alkylating agents 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) and methyl methanesulfonate (MMS). The protection by the chimeric protein against BCNU is even greater than MGMT alone, which has potential translational significance given that MGMT is currently in clinical trials. Additionally, we show that the chimeric MGMT-Apn1 protein can protect mammalian cells from dual treatments of BCNU and MMS and that this effect is greater than that provided by MGMT alone. The data support our previous finding that a protein with multiple DNA repair activities can be constructed and that this and other constructs may play an important clinical role in guarding against dose-limiting effects of chemotherapy, particularly in situations of multiple drug use.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hansen WK, Kelley MR . Review of mammalian DNA repair and translational implications. J Pharmacol Exp Ther. 2000;295:1–9.
Wadhwa PD, Zielske SP, Roth JC, Ballas CB, Bowman JE, Gerson SL . Cancer gene therapy: scientific basis. Annu Rev Med. 2002;53:437–452.
Hansen WK, Deutsch WA, Yacoub A, Xu Y, Williams DA, Kelley MR . Creation of a fully functional human chimeric DNA repair protein. Combining O6-methylguanine DNA methyltransferase (MGMT) and AP endonuclease (APE/redox effector factor 1 (Ref 1)) DNA repair proteins. J Biol Chem. 1998;273:756–762.
Limp-Foster M, Kelley MR . DNA repair and gene therapy: implications for translational uses. Environ Mol Mutagen. 2000;35:71–81.
Jelinek J, Rafferty J, Cmejla R, et al. A novel dual function retrovirus expressing multidrug resistance 1 and O6-alkylguanine-DNA-alkyltransferase for engineering resistance of haemopoietic progenitor cells to multiple chemotherapeutic agents. Gene Ther. 1999;6:1489–1493.
Frosina G . Overexpression of enzymes that repair endogenous damage to DNA. Eur J Biochem. 2000;267:2135–2149.
Friedberg EC, Walker GC, Siede W . DNA Repair and Mutagenesis. Washington, DC.: ASM Press; 1995.
Gerson SL . Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol. 2002;20:2388–2399.
Gonzaga PE, Potter PM, Niu TQ, et al. Identification of the cross-link between human O6-methylguanine-DNA methyltransferase and chloroethylnitrosourea-treated DNA. Cancer Res. 1992;52:6052–6058.
Erickson LC, Laurent G, Sharkey NA, Kohn KW . DNA cross-linking and monoadduct repair in nitrosourea-treated human tumour cells. Nature. 1980;288:727–729.
Robins P, Harris AL, Goldsmith I, Lindahl T . Cross-linking of DNA induced by chloroethylnitrosourea is presented by O6-methylguanine-DNA methyltransferase. Nucleic Acids Res. 1983;11:7743–7758.
Samson L, Derfler B, Waldstein EA . Suppression of human DNA alkylation-repair defects by Escherichia coli DNA-repair genes. Genetics. 1986;83:5607–5610.
He YH, Wu M, Kobune M, Xu Y, Kelley MR, Martin WJ . Expression of yeast apurinic/apyrimidinic endonuclease (APN1) protects lung epithelial cells from bleomycin toxicity. Am J Respir Cell Mol Biol. 2001;25:692–698.
Ramotar D . The apurinic–apyrimidinic endonuclease IV family of DNA repair enzymes. Biochem Cell Biol. 1997;75:327–336.
Bregni M, Magni M, Siena S, Di Nicola M, Bonadonna G, Gianni AM . Human peripheral blood hematopoietic progenitors are optimal targets of retroviral-mediated gene transfer. Blood. 1992;80:1418–1422.
Bodine DM, Moritz T, Donahue RE, et al. Long-term in vivo expression of a murine adenosine deaminase gene in rhesus monkey hematopoietic cells of multiple lineages after retroviral mediated gene transfer into CD34+bone marrow cells. Blood. 1993;82:1975–1980.
Moritz T, Williams DA . Transfer of drug resistance genes to hematopoietic precursors. In: Bertino, J. R. ed. Encyclopedia of Cancer, Vol. III. San Diego: Academic Press; 1997: 1765–1776.
Dirven HA, Dictus EL, Broeders NL, van Ommen B, van Bladeren PJ . The role of human glutathione S-transferase isoenzymes in the formation of glutathione conjugates of the alkylating cytostatic drug thiotepa. Cancer Res. 1995;55: 1701–1706.
Rekha GK, Sreetama L, Sladek NE . Intrinsic cellular resistance to oxazaphosphorines exhibited by a human colon carcinoma cell line expressing relatively large amounts of a class-3 aldehyde dehydrogenase. Biochem Pharmacol. 1994;48:1943–1952.
Ueda K, Cardarelli C, Gottesman MM, Pastan I . Expression of a full-length cDNA for the human “MDR1” gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA. 1987;84:3004–3008.
Wang J, Chen Z, Xia X, Lu D, Xue J, Ruan C . Improvement of combination chemotherapy tolerance by introduction of polycistronic retroviral vector drug resistance genes MGMT and MDR1 into human umbilical cord blood CD34(+) cells. Leuk Res. 2002;26:281–288.
Suzuki M, Sugimoto Y, Tsuruo T . Efficient protection of cells from the genotoxicity of nitrosoureas by the retrovirus-mediated transfer of human O-6-methylguanine-DNA methyltransferase using bicistronic vectors with human multidrug resistance gene 1. Mutat Res Fundam Mol Mech Mut. 1998;401:133–141.
Kleibl K, Margison GP . Increasing DNA repair capacity in bone marrow by gene transfer as a prospective tool in cancer therapy. Neoplasma 1998;45:181–186.
Maze R, Kapur R, Kelley MR, Hansen WK, Oh SY, Williams DA . Reversal of 1,3-bis(2-chloroethyl)-1-nitrosourea-induced severe immunodeficiency by transduction of murine long-lived hemopoietic progenitor cells using O6-methylguanine DNA methyltransferase complementary DNA. J Immunol. 1997;158:1006–1013.
Maze R, Kurpad C, Pegg AE, Erickson LC, Williams DA . Retroviral-mediated expression of the P140A, but not P140A/G156A, mutant form of O6-methylguanine DNA methyltransferase protects hematopoietic cells against O6-benzylguanine sensitization to chloroethylnitrosourea treatment. J Pharmacol Exp Ther. 1999;290:1467–1474.
Gerson SL, Miller K, Berger NA . O6 alkylguanine-DNA alkyltransferase activity in human myeloid cells. J Clin Invest. 1985;76:2106–2114.
Evans AR, Limp-Foster M, Kelley MR . Going APE over ref-1. Mutat Res. 2000;461:83–108.
Tomicic M, Eschbach E, Kaina B . Expression of yeast but not human apurinic/apyrimidinic endonuclease renders Chinese hamster cells more resistant to DNA damaging agents. Mutat Res. 1997;383:155–165.
Mol CD, Izumi T, Mitra S, Tainer JA . DNA-bound structures and mutants reveal abasic DNA binding by APE1 and DNA repair coordination [corrected]. Nature. 2000;403:451–456.
Mol CD, Hosfield DJ, Tainer JA . Abasic site recognition by two apurinic/apyrimidinic endonuclease families in DNA base excision repair: the 3′ ends justify the means. Mutat Res. 2000;460:211–229.
Tainer JA, Friedberg EC . Dancing with the elephants: envisioning the structural biology of DNA repair pathways. Mutat Res. 2000;460:139–141.
Daniels DS, Tainer JA . Conserved structural motifs governing the stoichiometric repair of alkylated DNA by O(6)-alkylguanine-DNA alkyltransferase [In Process Citation]. Mutat Res. 2000;460:151–163.
Kreklau EL, Limp-Foster M, Liu N, Xu Y, Kelley MR, Erickson LC . A novel fluorometric oligonucleotide assay to measure O(6)-methylguanine DNA methyltransferase, methylpurine DNA glycosylase, 8-oxoguanine DNA glycosylase and abasic endonuclease activities: DNA repair status in human breast carcinoma cells overexpressing methylpurine DNA glycosylase. Nucleic Acids Res. 2001;29:2558–2566.
Acknowledgements
This work was supported by National Institutes of Health grants CA76643, NS38506, ES05865, ES03456, P01-CA75426, and P30 DK49218 supporting MRK, as well as DOD grants OC00113 and OC990085 to MRK. The Riley Memorial Association also supported these studies. We would also like to acknowledge the help of Emi Kreklau for MGMT activity assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Roth, T., Xu, Y., Luo, M. et al. Human–yeast chimeric repair protein protects mammalian cells against alkylating agents: enhancement of MGMT protection. Cancer Gene Ther 10, 603–610 (2003). https://doi.org/10.1038/sj.cgt.7700605
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700605